Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the…
conference
Treatment with evobrutinib, an experimental therapy for relapsing forms of multiple sclerosis (MS), reduced the size of inflammation-associated brain lesions in a Phase 2 clinical trial, data show. The oral medication was also found to be generally safe and well tolerated, according to an analysis of trial data in…
An upcoming conference focused on progressive multiple sclerosis (MS) will offer the latest insights about the underlying biology of the disease, and treatment and clinical strategies in development. The one-day conference, “Emerging Research & Trial Strategies for Progressive Multiple Sclerosis,” is taking place virtually on Oct. 4,and is…
An investigational immunotherapy, ATA188Â showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…
The National Multiple Sclerosis Society will host the second edition of its Black MS Experience Summit, a virtual event to help forge connections among those who understand the experience of living with multiple sclerosis (MS) as a Black person. Register here to join the interactive, two-day…
Selma Blair, the TV and film actor who is also a multiple sclerosis (MS) advocate, will headline next month’s second International Virtual Summit for young adults with chronic and rare disorders. Hosted by Health Advocacy Summit (HAS), the Aug. 7-8 event will focus on empowerment, resources, and connection. The event is…
Stop Multiple Sclerosis is the theme of this year’s World Brain Day, taking place July 22 to raise global awareness of multiple sclerosis (MS) through seminars, conferences and other presentations. “Every year, we use World Brain Day to highlight an area of neurology that needs the world’s attention,”…
The Consortium of Multiple Sclerosis Centers (CMSC) has launched a monthly webinar series, in partnership with NeurologyLive, to keep doctors and others treating people with multiple sclerosis (MS) informed of the latest in disease care and research. Called “The Ever Changing Face of MS,” the series opened on…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read the latest stories from the conference. A novel method to calculate how long it takes therapies for multiple sclerosis (MS) to become fully effective…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Vumerity (diroximel fumarate) continues to be safe and well-tolerated, in addition to reducing measures of disease activity in people…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. A majority of the relapsing-remitting multiple sclerosis (RRMS) patients given Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treatment with Tysabri (natalizumab) can improve mental and social health in people with multiple sclerosis (MS), according to new…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. The majority of people with multiple sclerosis (MS) experience new or worsening symptoms after developing COVID-19, a patient survey…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. When the weather is unusually warm, people with multiple sclerosis (MS) are more likely to require emergency medical care,…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. There is a lack of diversity among neurologists, who are disproportionately white men, but new programs aimed at inclusivity may…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. African Americans with relapsing-remitting multiple sclerosis (RRMS) are more likely than white patients — despite comparable disease durations and…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Note: This story was updated April 21, 2021, to clarify that Kesimpta will be available in the next three months…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the…
NeurologyLive and the Consortium of Multiple Sclerosis Centers (CMSC) have launched a new video series called Cure Connections, designed to provide healthcare professionals with expert news and insights about multiple sclerosis (MS). “These past several months our partnership with the CMSC has escalated to producing and disseminating extremely…
Columns
MS News That Caught My Eye Last Week: COVID-19 Vaccines, Benign and Aggressive MS, Cog Fog, Diet
All of the stories this week are from the ACTRIMS 2021 Forum, an MS research conference held virtually Feb. 25–27. #ACTRIMS2021 – COVID-19 Vaccines Safe for MS Patients, Minimally Affected by DMTs My wife and I received the second shot of the Moderna vaccine last week. (You can read…
Rising average temperatures may lead to a worsening of symptoms in people with multiple sclerosis (MS) and a greater need for hospital care, according to a preliminary study by researchers in the U.S. Its findings will be presented at the virtual annual meeting of the American Academy of Neurology,…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Women with multiple sclerosis (MS) who continue taking disease-modifying therapies (DMTs) throughout pregnancy accrue lower non-maternity healthcare…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. While researchers make progress in pinpointing markers of disease progression in multiple sclerosis (MS), identifying those that signal…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Cognitive impairment without physical disability in multiple sclerosis (MS) may grow in prevalence as newer therapies better control…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Reducing the essential amino acid methionine in the diet lessened multiple sclerosis (MS)-like symptoms in a mouse model of…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Dietary restriction can lessen the severity of multiple sclerosis (MS) by modulating levels of fat-related hormones, new research…
Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Clinical characteristics of multiple sclerosis (MS) patients, including their response to therapies, vary based on race and ethnicity,…